Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2- Advanced/Metastatic Breast Cancer Receiving Palbociclib + Aromatase Inhibitor (AI) Combination Therapy as First-Line Treatment

NCT04394247 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04394247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04394247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Patient Characteristics, Treatment Patterns, and Clinical Outcomes in Patients Diagnosed With HR+/HER2- Advanced/Metastatic Breast Cancer Receiving Palbociclib + Aromatase Inhibitor (AI) Combination Therapy as First-Line Treatment
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
June 30, 2020
Completion date
December 31, 2020
Enrollment
242 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer